Auspherix Appoints Dr. Neil Miller as Chief Scientific Officer

Stevenage, UK, 2 December 2015 – Auspherix Limited (UK), an early stage anti-infectives company, has announced the appointment of Dr. Neil Miller as its Chief Scientific Officer, effective 1 December.

As CSO, Dr Miller will take full responsibility for driving forward the Company’s antibiotic R&D programmes, both in house and through partners, into clinical Proof-of-Concept studies. The Company’s discovery platform has led to the invention of novel compound series with activity against both gram-positive and gram-negative bacteria.

Prior to joining Auspherix, Dr Miller has spent two decades in the pharmaceutical industry at GlaxoSmithKline (GSK), most recently as Senior Director and Head of Chemistry, DMPK & External Discovery in Singapore. In this role he led a research collaboration with the National University of Singapore, to evaluate monoclonal antibodies for the potential treatment of Dengue Fever.  Dr Miller has held a variety of managerial and scientific roles at GSK, including that of Site Head at GSK’s R&D Centre in Singapore.  He has a degree in Chemistry with Pharmacology and a PhD in Organic Synthesis from the University of Liverpool, UK.

Dr Miller replaces Professor Ian Charles, co-founder and previously consultant Chief Scientific Officer, who will continue to actively contribute to the Company’s scientific direction as both a member of the Board and as Chair of the Scientific Advisory Board.

Commenting on Neil’s appointment, Auspherix Chairman Dr Roberto Solari said: “At this stage, Auspherix needs a CSO with hands on scientific leadership and proven expertise in driving drug discovery. With a strong track record of progressing compounds into clinical development coupled with his extensive drug discovery experience and global perspective, Neil has the ideal mix of skills, and we are delighted that he has joined the Company.”

Dr Neil Miller, CSO added “Auspherix has achieved a huge amount to date and its pipeline of novel antibacterial compounds are showing very strong early potential against a broad range of multidrug resistant (MDR) important Gram-negative and Gram-positive bacterial infections. It is an exciting time to be joining the Company and I look forward to working with the R&D team, our partners, the Board and our investors to deliver on our potential.”

Having raised £6million earlier in 2015, Auspherix is well placed to make rapid progress in its quest to develop a new class of antibiotics that will strengthen the existing arsenal of antibacterial treatments. The Company is expanding its UK-based microbiology and management teams at the Stevenage Bioscience Catalyst and is intensifying its discovery research, and intends to explore further the potential in its antibiotic platform.

-Ends-

Notes for editors

About Auspherix Ltd

Auspherix Ltd has discovered a brand new class of antibacterials with a unique profile and novel mechanism of action that could overcome rising problems of resistance to current antibiotics. Its compound series show activity against a broad range of multidrug resistant (MDR) important Gram-negative and Gram-positive bacterial infections, with profiles consistent with their use as antibacterial drugs for a number of indications with high unmet need and large market potential.

Based in Stevenage UK (in the Stevenage Bioscience Catalyst facility), the Company was founded in late 2013 based on discoveries made at the ithree institute at the University of Technology Sydney (UTS). The Company has raised AUS $2million in Seed and Series A1 investments (2013-2014) from Australia’s Medical Research Commercialisation Fund (MRCF) and £6 million in Series A2 round (2015) from the MRCF and the UK’s Imperial Innovations plc (AIM IVO).

For further information please visit www.auspherix.com

For more information please contact:

Media Relations – Instinctif Partners

Sue Charles/ Gemma Howe/ Rosanna Forrest

T: +44 (0)20 7457 2020

E: auspherix@instinctif.com

Auspherix

Dr Neil Miller

T: +44 (0)1438 906755

E: neil.miller@auspherix.com

Auspherix and Domainex Expand Collaboration to Develop New Drugs that Tackle Antibiotic-Resistant Bacterial Infections

Cambridge, UK and Stevenage, UK – 15 September 2015 – Domainex and Auspherix today announce an expansion of their collaboration to develop new drugs to tackle the growing threat of resistance to antibiotics. The programme has been extended through to 2017.

Since initiating the project in 2014, significant progress has been made towards the invention of new compounds with activity against both gram-positive and gram-negative bacteria. The collaboration extension aims both to refine the current chemical series towards selection of novel pre-clinical candidates and to explore potential additional compound series. A team of at least five chemists will be deployed at Domainex providing analytical and medicinal chemistry expertise, working in partnership with Auspherix’s growing R&D team.

Eddy Littler, Chief Executive Officer of Domainex said, “We are very pleased to have expanded our partnership with Auspherix. This is a strong endorsement of the inventiveness, productivity and client-focus of our drug discovery services team. We will undertake further lead optimisation studies to build on the excellent progress made to date. Together with Auspherix, we are focused on the identification of novel pre-clinical drug candidates to address the growing global burden of multi-drug resistant bacterial diseases.”

Alongside the expansion of the medicinal chemistry programme with Domainex, Auspherix is building its UK-based microbiology and management teams at the Stevenage Bioscience Catalyst. It is intensifying discovery research on its initial bacterial disease focus, and intends to explore further the potential in its antibiotic platform.

Professor Ian Charles, co-founder and CSO of Auspherix said, “Having established operations in the UK, our initial programmes are on track and making excellent progress. We believe the novel mechanism of action of our compound series discovered jointly with Domainex’s scientists offers enormous potential for the development of a new arsenal of drugs that will be required to treat the growing numbers of bacterial infections.”

-Ends-

About Auspherix Ltd

Auspherix Ltd has discovered a brand new class of anti-bacterials with a unique profile and novel mechanism of action that could overcome the major global problem of antimicrobial resistance. Its compound series show activity against a broad range of multidrug resistant (MDR) gram-negative and gram-positive bacteria, with PK profiles consistent with their use as antibacterial drugs for a number of indications with high unmet medical need and large market potential.

Based in Stevenage UK (in the Stevenage Bioscience Catalyst facility), the Company was founded in late 2013 based on discoveries made at the ithree institute at the University of Technology Sydney (UTS). The Company has raised AUS$2 million in Seed and Series A1 investments (2013-2014) from Australia’s Medical Research Commercialisation Fund (MRCF) and £6 million in Series A2 round (2015) from the MRCF and the UK’s Imperial innovations plc (AIM IVO).

For further information please visit www.auspherix.com

About Domainex

Domainex Ltd. is a Cambridge-based small-molecule drug discovery company that provides integrated drug discovery services to pharmaceutical, biotechnology and academic partners globally. Services cover a wide span of the drug discovery value chain, from disease target validation to pre-clinical candidate nomination. Domainex’s services include recombinant protein expression and use of its proprietary technology platform, Combinatorial Domain Hunting to identify soluble protein fragments for structural biology and assay development. Hit finding activities encompass assay development and screening utilising its Bioassay Builder and LeadBuilder portfolios. The core of the service platform is undertaking multi-parameter medicinal chemistry optimisation of hits and leads under the mantra ‘every compound counts’, which can save up to 30% of average industry time.

Additionally, Domainex is investing in developing its own therapeutic compounds for out-licensing in two specific areas: 1) Inhibitors of the kinases TBK1 & IKK epsilon to treat inflammatory conditions such as COPD and psoriasis; 2) The emerging epigenetic target class of lysine methyltransferases potentially implicated in oncology, where to date Domainex has built a portfolio of drug discovery assets encompassing novel chemical matter, proprietary assays and crystal structures.

For more information please visit www.domainex.co.uk

For more information please contact:

Auspherix

UK and ROW

Roberto Solari, Chairman (UK and RoW)

Roberto.solari@auspherix.com

Tel: +44 (0)20 7594 3116

In Australia

Stephen Thompson, Director

sthompson@brandoncapital.com.au

Tel: +61 (0)404 153 957

Media relations (Instinctif Partners)

Sue Charles / Gemma Howe / Rosanna Forrest

auspherix@instinctif.xom

Tel: +44 (0)20 7866 7860

Domainex

Tom Mander, Chief Operating Officer

tom.mander@domainex.co.uk

Tel: +44 (0)7584 578024

Media Relations (Sciad)

Deborah Cockerill

deborah@sciad.com

M: +44 (0)7930 317729

James Motteram

james@sciad.com

Tel: +44(0)203 773 9580

Auspherix Expands Board of Directors and Scientific Advisory Board

Stevenage, UK, 22 July 2015 – Auspherix Limited (UK), an early stage anti-infectives company, has announced that it has expanded and strengthened its Board and Scientific Advisory Board with the appointments of Dr Jared Silverman as Non-Executive Director and Scientific Advisor, and Professor David Livermore as a Scientific Advisor.

Dr Silverman’s career has focused on the discovery and development of novel antibiotics to treat serious, drug resistant infections in the hospital setting. US-based, he is currently VP of Research at VL32, following 18 years at Cubist Pharmaceuticals. He has two decades of experience in converting basic science into clinically and commercially useful data to guide drug development, patient treatment and marketing strategy. His research has contributed to the discovery of three novel antibiotics that entered clinical development.

Professor Livermore brings a wealth of knowledge and expertise to the Company, with over 35 years in the sector and a long track record of research and publications on the evolution and epidemiology of antibiotic resistance, particularly b-lactamases. Currently Professor of Medical Microbiology at the University of East Anglia (UEA), he serves on the UK Government’s Antimicrobial Resistance & Healthcare Associated Infection Advisory Committee. Earlier in his career he spent 14 years with the Public Health Laboratory Service (now Public Health England), becoming Director of its Antibiotic Resistance Monitoring and Reference Laboratory, and 17 years at the London Hospital Medical College.

Commenting on the new appointments, Dr Roberto Solari, Non-Executive Chairman of Auspherix, said: “Being able to attract individuals of the quality and international standing of Jared and David underlines the potential that exists within Auspherix. Their decades of experience and achievement in the anti-infectives arena will be invaluable in helping to guide our discovery and development efforts.

“These appointments, along with other recent additions to our senior team, our move to the UK and securing £6m in venture financing means that we are well positioned to progress our discoveries of a new class of antibiotics with novel mechanisms of action. Finding ways to address the ever increasing issue of antibiotic resistance is critical to future medicine and we are pleased to be playing a role in that endeavor.”

Auspherix is actively recruiting to expand its science and management teams.

-Ends-

Notes for editors

About Auspherix Ltd

Auspherix Ltd has discovered a brand new class of antibacterials with a unique profile and novel mechanism of action that could overcome rising problems of resistance to current antibiotics. Its compound series show activity against a broad range of multidrug resistant (MDR) important Gram-negative and Gram-positive bacterial infections, with PK profiles consistent with their use as antibacterial drugs for a number of indications with high unmet need and large market potential.

Based in Stevenage UK (in the Stevenage Bioscience Catalyst facility), the Company was founded in late 2013 based on discoveries made at the ithree institute at the University of Technology Sydney (UTS). The Company has raised AUS $2million in Seed and Series A1 investments (2013-2014) from Australia’s Medical Research Commercialisation Fund (MRCF) and £6 million in Series A2 round (2015) from the MRCF and the UK’s Imperial innovations plc (AIM IVO).

For further information please visit www.auspherix.com

About Dr Jared Silverman

Dr Silverman’s career has focused on the discovery and development of novel antibiotics to treat serious, drug resistant infections in the hospital setting. US-based, he is currently VP of Research at VL32, following 18 years at Cubist Pharmaceuticals where he contributed to the discovery of three novel antibiotics that entered clinical development, including as the biology lead for the discovery of Surotomycin, currently in Phase 3 trials for the treatment of C. difficile.  Additionally, Dr Silverman and his collaborators pursued studies into the mechanism of action of the lipopeptide antibiotic daptomycin and the mechanisms of resistance to this clinically important antibiotic. He undertook postdoctoral training at Yale University and has a PhD in Microbiology from Harvard Medical School. Dr. Silverman serves as a member of the UK MRC’s Antimicrobial Resistance steering group.

About Professor David Livermore

Professor Livermore brings a wealth of knowledge and expertise to the Company, with over 35 years in the sector and a long track record of research and publications on the evolution and epidemiology of antibiotic resistance, particularly b-lactamases. Currently Professor of Medical Microbiology at the University of East Anglia (UEA), he serves on the UK Government’s Antimicrobial Resistance & Healthcare Associated Infection Advisory Committee, and has contributed extensively to the Chief Medical Officer for England’s 2011 Annual Report.  Prior to this he spent 14 years with the Public Health Laboratory Service (now Public Health England), becoming Director of its Antibiotic Resistance Monitoring and Reference Laboratory.  Within his current UEA role, he continues to provide sessions to Public Health England as its Lead on Antibiotic Resistance. In his earlier career, Professor Livermore spent 17 years at the London Hospital Medical College.  He has edited for several journals, presently including the International Journal of Antimicrobial Agents.  David has a PhD in Medical Microbiology from the University of London. He consults widely for the pharmaceutical industry.

For more information please contact:

Media Relations – Instinctif Partners

Sue Charles/ Gemma Howe/ Rosanna Forrest

T: +44 (0)20 7457 2020

E: auspherix@instinctif.com

Auspherix

In the UK

Dr Roberto Solari, Chairman

T:  +44 (0)20 7594 3116

E: Roberto.solari@auspherix.com

In Australia

Dr Stephen Thompson, Director of Auspherix and Partner at Brandon Capital (manager of the MRCF)

T +61 (0)3 9657 0700

E: SThompson@brandoncapital.com.au

Auspherix Appoints Experienced Anti-Infectives Clinician to Scientific Advisory Board

Auspherix, an early stage anti-infectives company, today announces that it has expanded its Scientific Advisory Board (SAB) with the appointment of highly experienced clinician, Professor William Hope.

William’s career to date has focused on research in antimicrobial pharmacokinetics and pharmacodynamics, mathematic modelling of antimicrobial agents and individualisation of antimicrobial therapy.  He is an NIHR Clinical Scientist and Professor of Therapeutics and Infectious Diseases at The University of Liverpool, UK and was recently appointed as Chair in the Department of Molecular and Clinical Pharmacology at The University of Liverpool. A Fellow of the Royal Australasian College of Physicians and the Royal College Pathologists of Australasia. He was previously Chair in Therapeutics and Infectious Diseases at The University of Manchester. He has a PhD in antimicrobial pharmacology from The University of Manchester.  Alongside his advisory role to Auspherix, William is also Scientific Advisor to the ESCMID Fungal Infection Study Group, Secretary to the EUCAST Antifungal Susceptibility Testing Sub-Committee and was recently appointed to the ICAAC Program Committee for Antimicrobial Pharmacokinetics, Pharmacodynamics and General Pharmacology.

Founded in 2013, Auspherix is developing a new class of anti-bacterials with a unique profile suggestive of a novel mechanism of action.

Dr Neil Miller, CSO of Auspherix, said: “With his hands on clinical experience, and a depth of knowledge gained during his careers in the anti-infectives space, William’s input and guidance will make an invaluable addition to the insight and steer we get from our SAB as we progress our novel anti-bacterial drug candidates through pre-clinical development towards our first-in-human clinical trial.”

The Auspherix’s SAB is chaired by Professor Ian Charles, co-founder and previously CSO of the Company, and now Director of the Institute of Food Research/Quadram Institute. He has a strong focus on translational research and infectious diseases, and was previously co-founder and CSO of Arrow Therapeutics. As well as new member Professor William Hope, other SAB members are: Auspherix CSO Neil Miller; Auspherix Board member Dr Jared Silverman, VP of Research at VL32 and who contributed to the discovery of three novel antibiotics during his career within Cubist Pharmaceuticals; Dr Alan Naylor, an independent consultant and medicinal chemist with over 30 years of R&D experience within GlaxoSmithKline; and Professor David Livermore, Professor of Medical Microbiology at the University of East Anglia  and serves on the UK Government’s Antimicrobial Resistance & Healthcare Associated Infection Advisory Committee.

-Ends-

Notes to Editors

About Auspherix Ltd

Auspherix Ltd has discovered a novel class of antibacterials with a unique profile suggestive of a novel mechanism of action and therefore offer the potential to address the rising global problem of resistance to current antibiotics. Its compound series show activity against a broad range of multidrug resistant (MDR) important Gram-negative and Gram-positive bacterial infections, with profiles consistent with their use as antibacterial drugs for a number of indications with high unmet need and large market potential.

Based in Stevenage UK (in the Stevenage Bioscience Catalyst facility), the Company was founded in late 2013 based on discoveries made at the ithree institute at the University of Technology Sydney (UTS). The Company has raised AUS $2million in Seed investments (2013-2014) from Australia’s Medical Research Commercialisation Fund (MRCF) and £6 million in Series A round (2015) from the MRCF and the UK’s Imperial innovations plc (AIM IVO).

For more information please contact:

Media Relations – Instinctif Partners

Sue Charles / Gemma Howe / Rosanna Forrest

T: +44 (0)20 7457 2020

E: auspherix@instinctif.com

Auspherix

Dr Neil Miller

T: +44 (0)1438 906755

E: neil.miller@auspherix.com

Auspherix Raises £6Million to Progress its Novel Antibiotics and Establishes UK Operations

Stevenage, UK, 3 June 2015 – In the race to develop new antibiotics with completely new modes of action that might address the growing threat posed by antimicrobial resistance, Auspherix Limited (UK), an early stage anti-infectives company originated in Sydney Australia, has raised £6 million in a Series A venture financing, and is establishing operations on the Stevenage Bioscience Catalyst site just outside of London, UK. New investor Imperial Innovations plc (AIM IVO) led the round alongside Australian founding investor the Medical Research Commercialisation Fund (MRCF).

The investment will be used to fund the Company’s drug discovery programme, expand the experienced management team and recruit a world-class microbiology team. Auspherix aims to progress its novel class of antibacterials, which have a unique profile and novel mechanism of action, through lead optimization to final candidate selection within the next two years. Auspherix’s current lead compounds show activity against a broad range of multidrug resistant (MDR) important Gram-negative and Gram-positive bacterial infections.

The Company was co-founded by Professor Ian Charles and Dr Dagmar Alber during their time together at the ithree institute, UTS, Sydney. Dr Roberto Solari has joined the Board of Directors as its independent non-executive Chairman. Previously, Dr Solari was Vice President in GSK’s UK-based Respiratory Therapy Area, and is currently senior research fellow in the National Heart and Lung Institute, Imperial College London, focusing on respiratory infections. He is also an advisor to Imperial Innovations and Brandon Capital Partners, and is on the board of Heptares and the Science Advisory Board of Astex Pharmaceuticals. Before joining GSK, Dr Solari was CEO of the UK Medical Research Council’s technology transfer arm, MRCT, creating spin out companies such as Heptares and developing an internal drug discovery group. The Company has also appointed Grant Hawthorne, an experienced biotech company director as COO.

Founding venture investor and Auspherix Board member Dr Stephen Thompson, Partner at Brandon Capital Partners, the Australian venture capital firm that manages the MRCF, said: “Auspherix has progressed very rapidly and is now at the stage that building out the team is appropriate. The potential of the Company’s new class of anti-infectives is an extremely exciting opportunity and I am delighted that Imperial innovations has agreed to invest alongside the MRCF to move the programmes forward.”

Commenting on the investment and Auspherix’s potential, Dr Solari said: “Auspherix’s novel chemistry has activity against a broad range of multidrug resistant (MDR) Gram-negative and Gram-positive bacterial infections and the initial pharmacokinetic profile of these compounds is consistent with their use as an antibacterial drug for a number of indications with high unmet need and large market potential.”

Professor Charles, co-founder and CSO said “The need to find new ways to combat infectious diseases becomes more urgent year-on-year as superbugs continue to emerge that are resistant to more and more current antibiotics. Whilst drug discovery is a long road, to have discovered antibacterial compounds with completely novel chemical structures is very exciting and I look
forward to working with the new team as we move our discoveries forward towards the clinic
.”

The Company anticipates appointing a CEO within the coming months, and is building out its Stevenage-based R&D team. It will pursue a flexible investment and partnering model aimed at maximizing the speed with which it can develop and commercialize its novel antibiotic drug candidates.

-Ends-

Notes for editors

About Auspherix Ltd
Auspherix Ltd has discovered a brand new class of antibacterials with a unique profile and novel mechanism of action that could overcome rising problems of resistance to current antibiotics. Its compound series show activity against a broad range of multidrug resistant (MDR) important Gram-negative and Gram-positive bacterial, with PK profiles consistent with their use as antibacterial drugs for a number of indications with high unmet need and large market potential.

Based in Stevenage UK (in the Stevenage Bioscience Catalyst facility), the Company was founded in late 2013 based on discoveries made at the ithree institute at the University of Technology Sydney (UTS). The Company has raised AUS$2 million in in Seed and Series A1 investments (2013-2014) from Australia’s Medical Research Commercialisation Fund (MRCF) and £6 million in Series A2 round (2015) from the MRCF and the UK’s Imperial innovations plc (AIM IVO)).

For further information please visit www.auspherix.com.

About Imperial innovations
Imperial Innovations Group plc creates, builds and invests in pioneering technologies developed from the academic research within the ‘Golden Triangle’ broadly bounded by London, Cambridge and Oxford, which is home to the UK’s four leading research-intensive universities.

This area is home to many new technology companies through its proximity to the academic communities of Imperial College London, the University of Cambridge, the University of Oxford and University College London, as well as other leading research institutions.

Imperial College London, the University of Cambridge, the University of Oxford and University College London collectively have research income of £1.4 billion per annum and are ranked as four of the top ten Universities in the world (source: QS World University Rankings 2014/15).

Innovations supports scientists and entrepreneurs in the commercialisation of their ideas through the licensing of intellectual property, by leading the formation of new companies, providing facilities in the early stages, providing investment and encouraging co-investment to accelerate development, providing operational expertise and recruiting high-calibre management teams. It also runs an incubator in London that is the initial home for many of its technology spin-outs.

Since admission of its shares to trading on AIM in 2006, Innovations has raised more than £346.0 million of equity from investors, which has enabled it to invest in some of the most exciting spin-outs to come out of UK academic research. In addition, the Group has a £30.0 million loan facility from the European Investment Bank (EIB) for investment in biotech and therapeutics businesses.

During the period from admission on AIM up until 31 January 2015, Innovations has invested a total of £198.3 million across its portfolio companies, which have raised collectively investment of £926.8 million rising to £1.0 billion including post period end investments and commitments.

For further information please visit www.imperialinnovations.co.uk.

About The Medical Research Commercialisation Fund (MRCF)
The MRCF Collaboration, managed by Brandon Capital Partners, brings together over 50 of Australia’s leading medical research institutes and research hospitals in an innovative investment collaboration. The MRCF provides dedicated investment funding to support the commercialisation of early-stage medical research discoveries that originate from its members.

AU$200m MRCF3 fund launched in 2015 is supported by AustralianSuper, StatewideSuper, HESTA and HOSTPLUS industry superannuation funds. The MRCF’s first two funds, the MRCF Trust and MRCF IIF LP, totalling AU$51m were established in 2007 and 2011 and were supported by AustralianSuper, StatewideSuper and the Australian Government through its Innovation Investment Fund (IIF) program. The MRCF acknowledges support from the State Governments of Victoria, New South Wales, Western Australia, Queensland and South Australia.

For further information please visit www.mrcf.com.au andwww.brandoncapital.com.au.

For more information please contact:

Media Relations – Instinctif Partners
Sue Charles/ Gemma Howe/ Rosanna Forrest
T: +44 (0)20 7457 2020
E: auspherix@instinctif.com

Auspherix

In the UK
Dr Roberto Solari, Chairman
T: +44 (0)20 7594 3116
E: Roberto.solari@auspherix.com

In Australia
Dr Stephen Thompson, Director of Auspherix and Partner at Brandon Capital (manager of the MRCF)
T +61 (0)3 9657 0700
E: SThompson@brandoncapital.com.au

Please click on the link below to download the full Press Release:-

Auspherix Raises £6Million to Progress its Novel Antibiotics and Establishes UK Operations